still pimping GALE heh ?
Steve Kriegsman, CytRx and Mark Ahn, Galena Biopharma
These two are the Emperor Palpatine (Sith Lord) and Anakin Skywalker (Darth Vader) of biotech.
Under Mark Ahn's direction, Galena hired a group of stock touts to write and publish misleading articles across the Internet under false, assumed names. After the promotional campaign contributed to a tripling of Galena's stock price, Ahn and other insiders sold millions of dollars in company stock.
One of those profiting insiders was Steve Kriegsman, a Galena director. The scheme worked so well at Galena that Kriegsman, as CEO of CytRx, hired the same group of stock touts to promote his own company.
Their plans worked great until a pesky member of the media (ahem) started poking around. The stock prices of Galena and CytRx tanked and the friendly folks at the Securities and Exchange Commission launched an investigation into Galena (still ongoing.) Ahn was fired. Kriegsman was promoted to Chairman and CEO of CytRx. Unbelievable, except if you remember that CytRx's board is packed with Kriegsman cronies who awarded themselves sweetly priced options last December.
aqn, look at ACHN secondary offer on Jan 15,@$12.80, and now @$10.50.. what is your point by making these one tracked mind references ? CLDX offered secondary last year @$24.50 and it dropped to $12 within 6 months... stock NOT always go up after the secondary, so stop the mindless pumping..
Congratulations for making my point !! money has nothing to do with being classy...
apparently you and J20 like to compete in a rat race.. even if you win, you're still a rat..
j20, you are the living proof of "money can't buy you class"... the reason WS have words like bio-scam, and biotech bubble burst for a reason... late phase clinical trial failure is normal, so don't count your chickens before they hatch... don't you know anything ??
"Bibi talks out both sides of their mouth" as Jon Steward had pointed out on The Daily Show tonight.. !!!!!!!
anyone can turn salt water into fresh and can turn any desserts into Oasis .. with $4bil annual aids from the American tax money for over 60 years....
one big surprise is the ungratefulness and back stabbing by the beggers ...
SQUEEZE in your SHORT does not qualify as SHORT SQUEEZE Frank... accept the reality and move on...
fact, that is an insulted to HS kid... no one was that im-matured in HS nowaday..
next time you need to hit the nail on his head... LOL
J20, money can't buy you class, and you're the living proof of that.. I know you're a slow learner because you have repeatedly endorsed/initiated SA publications as the main source for the biotech investments, so someone had to speak up to reject the notion of your stupidity.
DNDN, AVEO, NQ Mobile are a few examples of how SA's faked analysis to scam investors to invest in high speculative outcomes. while SA was pumping the stocks, their employers (Hedge funds) shorted the stocks, and the rest is history..
I keep bringing up the DNDN because it was in the Onco space and it just happened recently, so data can be easily verified before these headlines get deleted from the websites to cover their tracks.. DNDN and AVEO were trumped up by SA as promising cancer drugs with deep pipelines while they were in the late stage clinical trials. Investors invested more than $120Mil in cash through secondary.. they start discontinued many PI/II clinical trials after they get their cash.. SA have used the same "Pump 'n Dump" tactics for more than 50 companies ..
CLDX has a similar compelling story as DNDN, AVEO and other cancer treatment companies that have "rise and fall" .. if CLDX made to the end-zone, they are the first and the only one.. GL..
are you guys that desperate to use the SA article of your base for investments ?
Here's a fine example of how SA articles continuous pumping DNDN until it declared bankruptcy..
why do you think YHOO is no longer allowed SA in their news outlet ? because SA writers get paid by company and hedge funds to scam investors.. these headlines can be found on YHOO finance websites.. these 2 nicks "temporal" and "J20" are paid to promote bogus SA articles.. don't buy in their BS..
Nov 12, 2014 ROTH Capital Upgrade to buy DNDN.
Monday, November 10, 2014: Dendreon declares bankruptcy CNBC (Mon, Nov 10)
Thursday, July 24, 2014: 3 Convincing Reasons To Buy Dendreonat Seeking Alpha (Thu, Jul 24)
Monday, July 7, 2014: New Provenge Data: Why Deerfield Investments Acquired A More Than 5% Stake In Mayat Seeking Alpha (Mon, Jul 7)
What Does Dendreon Need To Succeed?at Seeking Alpha (Mon, Jul 7)
Tuesday, June 24, 2014: Dendreon May Still Be In Play at Seeking Alpha (Tue, Jun 24)
Wednesday, June 18, 2014: 3 Terrific Reasons To Buy Dendreonat Seeking Alpha (Wed, Jun 18)
Dendreon: An Update On The Debt Situationat Seeking Alpha (Wed, Jun 18)
Monday, June 9, 2014: Dendreon CEO Leaves: Buyout Or Bankruptcy?at Seeking Alpha (Mon, Jun 9)
grey, do you think it is legal for company to set their stock price with institutions in private meeting ? secondly, is it legal to discuss inside information with selected audiences ?
if you know details about this case, then you need to contact SEC or FBI right away.. otherwise...it is wise to stop making a fool of yourself..
mbb, J20 is one of many institutional investor. he can't meet with you because he's in an institution.. they don't let him out until 2020.. give it up MBB... LMAO
you need to take your own advises and educate yourself about investing and raising hope for cancer patients.. many bio companies are exploiting this kind of emotion to raise money for their own curiosity. Unfortunately many have failed, they have wasted a lot of time and resources but produced nothing.. so CLDX is not the exception b/c they are not the first R&D in this space.... they just like any other cancer R&D company.
wrt 100 to $200 PPS for companies that have no cure cancer drug, then CLDX is already priced $2.3 Bil market cap w/o a cancer drug on the market... do you think CLDX is a bit over-priced ? if it is NOT, then what is the fair value for CLDX at this time ?
FDA data shows high % of late stage failures due to harder treatment for rare diseases, if you believe in science/statistic, then you should expected the worst and hope for the best..
another data point for you to consider, 35-40% of CLDX daily volume is short.. do you think they're irrational or logic of the probability dictates their behavior ? GL on your analysis...
I'm wrong all the time, so what is your point ??
investment is about making money... you're so insist about being right or wrong... if you want to talk about being right, then go talk to a priest... if you want to make money, then learn how to trade, not spending a lot of time being a mindless speculator and name callin' like a juvenile .. CLDX clinical data shows only marginal improvement over one drug, not a slam dunk, cure all cancer drug that over-hyped by pumpers on this MB..
Since the result is marginal, one trial may look favorable, the next trial could get negative results.. nothing is robust about bio clinical trial results, FDA approval is NOT guarantee, and jury is still out on revenue generation.. it is immature to conclude that CLDX has a secret sauce to cure cancers at this stage. GL